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To describe the clinical and demographic characteristics of fatal hepatitis due to single-drug isoniazid
preventive therapy for tuberculosis, we did a survey of cases from state health departments, published
case reports, and reports to the Centers for Disease Control and Prevention from 1970 to 1992. Of 108
reported cases, some clinical information was available for 76. A medical review panel judged 39 of
these deaths as probably due to isoniazid hepatitis and 23 deaths as possibly due to isoniazid hepati-
tis. Of the 62 probable and possible cases combined, 50 (81%) were female, 49 (79%) were non-His-
panic black or Hispanic, and 19 (31%) were younger than 35 years. The median duration of isoniazid
preventive therapy before symptom onset was 16 weeks. Of the 60 cases with symptom information,
54 (90%) presented with jaundice. Of the 62 cases, 26 (42%) were monitored monthly in accordance
with current recommendations, and 6 of the patients were younger than 35 years. We estimate that
the rate of fatal isoniazid hepatitis among patients in the public sector was no greater than 4.2 per
100,000 persons beginning therapy and no greater than 7 per 100,000 persons completing therapy.
Adherence to isoniazid preventive therapy guidelines apparently reduces, but does not eliminate, the
risk of fatal hepatitis. Careful patient selection, education, and monitoring are critical for minimizing
that risk.
(Millard PS, Wilcosky TC, Reade-Christopher SJ, Weber DJ: Isoniazid-related fatal hepatitis. West I Med 1996; 164:
486-491)
Since its introduction in 1952, isoniazid has been
widely used as a single agent to prevent active tuber-
culosis in persons infected with Mycobacterium tubercu-
losis. It is currently the only agent approved by the US
Food and Drug Administration (FDA) for that purpose.
Early clinical trials demonstrated the effectiveness of iso-
niazid preventive therapy and failed to show clinically im-
portant toxicity.'-3 Case series4`6 and cohort studies7'9
subsequently revealed, however, that administering isoni-
azid can rarely result in serious hepatotoxicity and death.
The Centers for Disease Control and Prevention
(CDC), Atlanta, Georgia, and the American Thoracic So-
ciety have recommended isoniazid preventive therapy,
with interim modifications of the indications for its use,
since 1965.s-17 Isoniazid preventive therapy plays a large
role both in the 1989 strategic plan to eliminate tubercu-
losis and the 1992 action plan to combat multidrug-
resistant tuberculosis.!8"'9 The increase in tuberculosis
incidence rates since 1985 in the United States has
prompted a renewed emphasis on tuberculin skin test
screening and isoniazid preventive therapy.20 In addition,
isoniazid is effective in preventing tuberculosis in persons
infected with the human immunodeficiency virus (HIV).2'
Reports of fatal isoniazid-associated hepatitis2224 have
reignited debate about the widespread use of isoniazid
preventive therapy.`27
A recent search of available databases found 177 pos-
sible cases of fatal isoniazid hepatitis in the United States
between 1965 and 1989.1 The study lacked clinical infor-
mation about the suspected cases, however, and the au-
thors could not be certain that all had indeed taken
isoniazid preventive therapy. Although published reports
of specific cases typically include clinical information,
they lack a uniform case definition, and they usually do
not reflect a systematic case-finding effort.' In one report,
the rate of fatal isoniazid hepatitis was estimated to be 14
per 100,000 persons who started isoniazid therapy.' In an-
other the rate of fatal isoniazid hepatitis was estimated to
be 1 per 100,000.29 The limitations of these data result in
considerable uncertainty concerning the magnitude of fa-
tal liver toxicity from isoniazid preventive therapy.
As part of a CDC-sponsored study of risk factors for
fatal hepatitis from isoniazid preventive therapy, we at-
tempted to obtain clinical data for all suspected cases in
the United States from 1970 to 1992 for subsequent re-
view by an expert panel. We describe the cases and indi-
cate where possible whether the CDC guidelines for
isoniazid preventive therapy were followed.
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Patients and Methods
Potentially eligible cases were those who reportedly
died in the United States of isoniazid-related hepatitis
from 1970 to 1992 after receiving preventive therapy with
isoniazid as the single antituberculous agent. In our
search for cases, we pursued all those reported in the
medical literature, and we contacted all state health de-
partments and those of selected large metropolitan areas.
When state health departments lacked a centralized re-
porting mechanism for suspected cases, we also contacted
local health departments in areas that reported a substan-
tial number of active tuberculosis cases. In addition, the
CDC Division of Tuberculosis Elimination provided a list
of suspected cases that had come to their attention. Al-
though other data sources (such as the FDA Adverse Re-
action Reporting System and the National Center for
Health Statistics multiple-cause death tapes) include re-
ports of possible cases,2 patient identifiers that could lead
to medical records are not available from these sources.
We collected all available clinical information for sus-
pected cases: health department records, hospital records,
histology reports and liver tissue sections, postmortem ex-
amination results, and death certificates. A medical panel
reviewed all records and tissue sections for suspected
cases; the panel comprised an infectious disease special-
ist, a gastroenterologist specializing in hepatology, and a
pathologist skilled in liver diseases. The medical review
panel used a case definition similar to that used in the US
Public Health Service Cooperative Surveillance Study of
1971 to 19738:
* Serum aspartate aminotransferase (AST) level at
least five times the laboratory's normal level, or clinical
symptoms likely due to hepatitis-jaundice, abdominal
pain, nausea, vomiting, malaise, fever, headache, arthral-
gias, and myalgias.
* No evidence of other causes of hepatitis: blood tests
positive for viral hepatitis, liver biopsies indicating he-
patitis from toxins other than isoniazid, or reports of ex-
posures to possibly fatal hepatotoxins near the time of
diagnosis.
The panel assessed all available information, includ-
ing the presence or absence of reported risk factors for
isoniazid hepatitis, and classified cases as probable (death
was likely due to isoniazid hepatitis), possible (consistent
with isoniazid hepatitis, but other causes were possible),
or unverifiable. High serum aminotransferase levels and
tests negative for hepatitis B surface antigen (HBsAg)
were generally necessary for a case to be judged proba-
ble. If the data were insufficient to exclude other causes
(where only a death certificate was available) the case was
judged unverifiable. In the few instances where panel




Authors of published articles and health department
staff members reported 108 possible cases of fatal isoni-
azid-related hepatitis from 1970 to 1992. No state health
department had comprehensive machine-retrievable
records for identifying suspected cases, and manual
searches to identify cases were rarely feasible because of
the large volume of records. Therefore, the case-finding
effort largely depended on the "institutional memory" of
the health department staff. Our search uncovered consid-
erably fewer cases than the 177 reported by others,' pri-
marily because these authors included suspected cases
from FDA Adverse Reaction Reports and from the Na-
tional Center for Health Statistics mortality tapes (from
which we could obtain no additional information). We
also found that some of the previously reported suspected
cases were ineligible for various reasons-such as nonfa-
tal cases, duplicate reports, and suicide. In addition, pre-
viously reported suspected cases that were unknown to
health department staff are excluded from our count, and
several recent suspected cases not included previously are
included here.
Descriptions of some suspected cases were published
in more than one report. Several published reports de-
scribed suspected cases that occurred in Maryland6'83"'
and California.21'3'-3 Moreover, one of six cases reported
jointly'6A had been described by others.5' We obtained at
least some records for 37 of the 49 published cases and
for 39 additional suspected cases, for a total of 76 (70%)
of the 108 suspected cases. The two most common rea-
sons for failing to obtain documentation were the unavail-
ability of the suspected case's name and the purging of
old medical records. In at least five instances, ongoing
lawsuits prevented our access to medical records.
Of the 76 suspected cases with documentation, 5 were
ineligible: 2 had been treated with several antituberculous
drugs, 2 had active tuberculosis, and 1 had no docu-
mented isoniazid exposure. The medical review panel
therefore evaluated 71 suspected cases. A total of 39
deaths (55%) were judged as probably due to isoniazid
hepatitis, 23 deaths (32%) were judged as possibly due to
isoniazid hepatitis, and for 9 deaths (13%) the diagnosis
was unverifiable.
Region IX of the CDC (Arizona, California, Hawaii,
and Nevada) had the largest reported number of probable
and possible cases, with 20 (32% of the 62 cases); all but
1 of these cases were from California. Of the 20 Califor-
nia cases reported earlier,' 11 were considered probable,
3 were possible, 2 were ineligible, and 4 had no available
records. Region III (Delaware; Washington, DC; Mary-
land; Pennsylvania; Virginia; and West Virginia) and
Region IV (Alabama, Florida, Georgia, Kentucky, Missis-
sippi, North and South Carolina, and Tennessee) each had
ABBREVIATIONS USED IN TEXT
AST = aspartate aminotransferase
CDC = Centers for Disease Control and Prevention
FDA = US Food and Drug Administration
HBsAg = hepatitis B surface antigen
HIV = human immunodeficiency virus
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13 cases, and no other CDC region reported more than
5 cases.
Characteristics of Cases
Three cases were known to have received isoniazid
preventive therapy in the private sector; health depart-
ments apparently prescribed preventive therapy for all
other cases. Table 1 shows the age and sex of the 39 prob-
able and 23 possible cases. For probable and possible
cases combined, 50 (81%) were female. Almost 80% of
cases (49) were among non-Hispanic blacks or Hispanics
(Table 2). For the 35 cases (56%) with a known birth-
place, about half were foreign born (Table 3).
TABLE 1.-Age and Sex of Probable and Possible Cases of
Fatal Isoniazid Hepatitis, 1970 to 1992
Probable Possible Totol Cases,
Sex Age, yr Cases, No. Cases, No. No. 0%4
Female ... 0-14 1 1 2 (4)
15-34 1 0 2 1 2 (24)
35-64 1 6 1 4 30 (60)
65+ 5 1 6 (12)
Total female. 32 18 50 (100)
Male. 0-14 2 0 2 (17)
1 5-34 1 2 3 (25)
35-64 4 2 6 (50)
65+ 0 1 1 (8)
Total male....... 7 5 12 (100)
Details ofIsoniazid Preventive Therapy
Figure 1 shows the duration of isoniazid preventive
therapy before the onset of hepatitis symptoms. Of the
cases, 53 (85%) took isoniazid for 30 weeks or fewer be-
fore the onset of symptoms, and the median duration of
isoniazid preventive therapy before symptoms began was
16 weeks. Of the 62 patients, 5 (8%) were known to have
taken isoniazid intermittently during their course of pre-
Probabie Possible Total Cases.
Race-E hnicity Cases, No. Cases, No. No. (So)
White, non-Hispanic ......... 7 5 12 (19)
Black, non-Hispanic .16 15 31 (50)
Hispanic. 16 2 18 (29)
Asian .0 1 1 (2)
Total .39 23 62 (100)
TABLE 3.-Foreign and US-Bom Probable and Possible
Cases of Fatal Isoniazid Hepatitis
Probable Possible Total Cases,
Birthplace Cases, No. Coses, 'o. Na. '°N )
Foreign... ... 14 5 19 (31)
United States ............. 6 10 16 (26)
Unknown ....... 19 8 27 (44)
Total .. ... 39 23 62 (100)
Figure 1.-The duration of isoniazid therapy in weeks before the
onset of hepatitis symptoms is shown for probable (shaded
bars) and possible (black bars) cases.
ventive therapy, and 3 had previously received isoniazid
preventive therapy.
Among the 57 cases with data on the duration of ther-
apy, treatment was continued as long as three months af-
ter the onset of symptoms (Figure 2). For two cases,
however, isoniazid therapy reportedly ended before the
onset of symptoms, and in an additional five cases (9%),
therapy was reportedly stopped on the day symptoms be-
gan (Figure 2 does not include these 7 cases). In six of the
cases ( 1%) shown in Figure 2, therapy was ended within
three days of the onset of symptoms.
The monitoring of patients for adverse medication re-
actions was variable. For one possible and three probable
cases (all occurring before 1982), follow-up was done
once every three months. In contrast, 26 cases (42%)
were monitored at least monthly; of these patients, 6 were
younger than 35 years.
Figure 2.-The duration of hepatitis symptoms in days before
stopping isoniazid therapy is shown for probable (shaded bars)
and possible (black bars) cases. In addition, 5 patients stopped
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Possible Contributing Factors
Because some medical records were incomplete, pa-
tients may have had contributing factors that did not ap-
pear in their charts. Thus, the reported numbers likely
underestimate the actual numbers. In 14 cases (23%), the
patients drank moderate to excessive amounts of alcohol
or had a history of alcohol abuse. In 28 cases (45%), the
patients were taking either possibly hepatotoxic drugs or
drugs that could have exacerbated the hepatotoxicity of
isoniazid. Possibly hepatotoxic drugs reported for at least
two cases included acetaminophen (6 cases); aspirin (4
cases); hydrochlorothiazide (4 cases); and erythromycin,
tetracycline, amitriptyline, and phenytoin (2 cases each).
No patients were known to have underlying disease
associated with liver dysfunction or to have long-term ex-
posure to environmental hepatotoxins. With the exception
of one patient for whom the HBsAg result was unknown,
all probable cases had negative HBsAg tests. Among pos-
sible cases, 13 were negative for HBsAg, 9 had unknown
results, and 1 was positive. Hepatitis A immunoglobulin
M antibodies were tested in 18 (46%) probable cases and
in 3 (13%) possible cases; all tests were negative. Hepati-
tis C serologic testing was done for one probable and one
possible case and was negative in both instances. The
only case known to have been tested for HIV infection
had a negative result.
Four women were pregnant at the time of starting
isoniazid preventive therapy. In addition, a 23-year-old
woman started isoniazid therapy when she was six
months postpartum. She was observed monthly, hepatitis
symptoms developed during the last month of the planned
six-month course, and she continued isoniazid for three
weeks after the onset of symptoms.
Clinical Course
Among the 60 probable and possible cases with avail-
able data about symptoms, 54 patients (90%) had jaun-
dice on presentation and 30 (50%) presented with nausea.
Other common symptoms at presentation included vom-
iting (25 [42%]), anorexia (23 [38%]), abdominal pain
(22 [37%]), and dark urine (21 [35%]). Fifteen patients or
fewer presented with changes in mental status, acholic
stools, fever, or fatigue.
We could sometimes obtain only a single liver func-
tion test result, and that measure may not have corre-
sponded to the patient's peak level. Furthermore, we often
did not know the laboratory-specific normal ranges for
aminotransferase levels. Nonetheless, the median peak re-
ported AST level was 1,230 units (interquartile range
[IQR], 636 to 2,478) in women (that is, 25% of women
had levels below 636, and 25% had levels above 2,478)
and 1,447 units (IQR, 1,200 to 3,455) in men. The median
peak total serum bilirubin level was 28 mg per dl (480
,umol per liter) (IQR, 21 to 35 [360 to 600 pumol per
liter]). The median time between the onset of symptoms
and death was 32 days (IQR, 24 to 48). For the 21 cases
with available information, the median liver weight at
death was 600 grams, and 32 (89%) of the 36 cases with
autopsy reports had histologic features of hepatic necro-
sis or acute yellow atrophy. In only 11 of the 43 cases
(26%) with death certificates was isoniazid mentioned as
a factor contributing to the death.
Appropriateness of Isoniazid Preventive Therapy
Six different sets of recommendations for isoniazid
preventive therapy were in effect during the study pe-
riod.t-t6 Table 4 shows the number of cases occurring in
each of the five periods and the authors' judgment con-
cerning the appropriateness of isoniazid preventive ther-
apy according to the guidelines in effect at the time. All
patients received appropriate doses of isoniazid. The four
deaths in women who were pregnant when isoniazid ther-
apy was started all occurred in the 1980s when the guide-
lines in effect recommended against starting isoniazid
preventive therapy during pregnancy. One 38-year-old
woman continued to receive isoniazid despite two nega-
tive tuberculin skin tests because she was a tuberculosis
contact. Another woman had previously received medica-
tion for a year as a participant in a Public Health Service
study in 1964-indicating that she may have been unnec-
essarily retreated with isoniazid in 1985 for a 20-mm tu-
berculin reaction. The 1964 medication, however, was not
definitely identified in the medical records as isoniazid, so
it was not possible to judge the appropriateness of the
treatment that led to her death.
Discussion
In a large eastern European clinical trial,' isoniazid
preventive therapy increased the risk of acute hepatitis by
fivefold, and the rate of fatal isoniazid hepatitis was 14
per 100,000 person-years. Estimates of the risk of death
from isoniazid hepatitis vary considerably, however, and
are affected by the characteristics of the population stud-
ied and by the degree of clinical vigilance that patients re-
ceive while taking isoniazid. In the Public Health Service
study of 1971 to 1973, the rate of fatal isoniazid hepatitis
was 55 per 100,000 person-years,8 but the unexpectedly
large number of deaths may have been related to local en-
vironmental factors in Baltimore, Maryland.'
A lack of reliable denominator data has precluded
making accurate estimates of the risk of fatal isoniazid
hepatitis in the general population.27 Snider and Caras,
however, estimated that at least 1,084,760 persons began
isoniazid preventive therapy in the United States during
1972 to 1988 and at least 655,867 completed therapy.2'
TABLE 4.-Appropriateness of Isoniazid Preventive Therapy Among
Combined Probable and Possible Cases of Fatal Isoniazid Hepatitis
Appropriate Inappropriate Insufficient
Treatment Period Therapy, No. Therapy, No. Dato, No.
1970 ...... 1 0 0
1971-1973 .... ......3 0 15*
1974-1983 .. ... 20 5 4
1984-1986 ... 5 0 1
1987-1990 . ...8 0 0
*In 13 cases, participants were from Maryland in the 1971-1973 US Public Health Service
study, and data were not available concerning indications for isoniazid prophylaxis.
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Assuming that the 46 fatal cases treated in the public sec-
tor during 1972 to 1988 that we identified represented the
totality of cases of fatal isoniazid hepatitis from that pop-
ulation, the estimated rate of fatal isoniazid hepatitis
was no greater than 4.2 per 100,000 persons beginning
therapy and no greater than 7 per 100,000 persons com-
pleting therapy. The estimated rates for 1984 to 1988-
during which time routine monitoring of hepatic enzyme
levels was recommended for persons older than 35 years
of age-were 1.7 per 100,000 starting therapy and 2.9 per
100,000 completing therapy.
Although recent case series have emphasized the dan-
gers of isoniazid preventive therapy,22'23'M decision analy-
sis suggests that the benefits of isoniazid preventive
therapy outweigh the risks,'M particularly when consider-
ing the additional benefits of preventing the spread of in-
fection to others.35 But without accurate data concerning
the risk of fatal hepatitis as a result of isoniazid preventive
therapy, decision analyses should be interpreted with cau-
tion. Rose and colleagues, for example, assumed that the
risk of death from isoniazid preventive therapy in persons
younger than 35 years of age is nil, which is not supported
by our data.
Among the 28 fatalities in cases from 15 to 50 years
of age, only 5 were men. In the absence of good denomi-
nator data, this finding is difficult to interpret, but the high
proportion of women in this age group among the cases
suggests that women of childbearing age may be at higher
risk than men for death from isoniazid hepatitis.
Of the cases, 26 (42%) were monitored monthly in ac-
cordance with current recommendations; 6 of these were
younger than 35 years and thought to be at low risk
for isoniazid hepatitis. Furthermore, 23 patients (38%)
stopped taking isoniazid within a week of the develop-
ment of symptoms of hepatitis, suggesting that a substan-
tial proportion of cases had a fatal outcome despite
appropriate monitoring. The relatively large proportion of
deaths that occurred among those younger than 35 years
is consistent with the findings of Snider and Caras.1 The
current guidelines, which do not advise routine monitor-
ing of hepatic enzymes for those younger than 35 years,'7
may need to be reconsidered in light of the relatively large
proportion of patients in this series who were young and
who died despite stopping the medication soon after
symptoms developed.
This case series is limited by incomplete case ascer-
tainment. We have calculated fatality rates by dividing the
number of cases treated in the public sector by the ap-
proximate number of persons who, according to Snider
and Caras, received isoniazid preventive therapy in the
public sector,28 but these estimates should be interpreted
with caution. Almost all the cases we identified had re-
ceived their care in the public sector, which suggests that
we may have failed to identify additional cases from the
private sector. For example, during our search we were
unaware of some of the recently reported cases associated
with liver transplant units in New York.' Manufacturers
of isoniazid have estimated that half of their sales are to
private sources,TM although the proportion used for preven-
tive therapy is unknown. We were reminded many times
while collecting the clinical data that the fear of litigation
is common; health care professionals may be reluctant to
attribute a patient's death to prescribed therapy. The ob-
stacles to reporting iatrogenic illness are great, and we ex-
pect that we underestimated the actual number of deaths
from isoniazid hepatitis. Furthermore, the cases we inves-
tigated had previously been subjected to sometimes rigor-
ous scrutiny, suggesting that some actual cases may have
been rejected by others on the basis of having other iden-
tified risk factors for hepatitis. Nonetheless, many of our
health department contacts were emphatic that if a case
had occurred, they would have known about it.
We attempted to collect data from each state regarding
the total number of persons treated annually with isoni-
azid preventive therapy, and we were struck by the lack of
organized systems for collecting such data. The United
States has no coordinated system for reporting fatal reac-
tions to isoniazid preventive treatment. The FDA has the
responsibility for monitoring drug toxicity, but only 2 of
the 20 deaths reported by Moulding and co-workers had
been reported to the FDA before the authors' investiga-
tion.22 Death certificates also appear to be an insensitive
means of detecting cases. The burden of proof for the
safety of preventive programs is high, and the comprehen-
sive national immunization toxicity surveillance program
could serve as a model for a similar program to monitor
tuberculosis preventive therapy.
In summary, isoniazid preventive therapy poses a
dilemma for physicians. Tuberculosis incidence rates are
rising, isoniazid prevents active tuberculosis in infected
persons, and no other drug can effectively replace isoni-
azid. A small proportion of patients experience serious
hepatotoxicity from isoniazid, however. Adherence to iso-
niazid preventive therapy guidelines apparently reduces,
but does not eliminate, the risk of fatal isoniazid-related
hepatitis. Although the risk is low, careful patient selec-
tion, education, and monitoring are critical for minimiz-
ing that risk.
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